DK2307393T3 - Fremgangsmåde til fremstilling af apoptosepromotoren ABT-263 - Google Patents
Fremgangsmåde til fremstilling af apoptosepromotoren ABT-263Info
- Publication number
- DK2307393T3 DK2307393T3 DK09767695.1T DK09767695T DK2307393T3 DK 2307393 T3 DK2307393 T3 DK 2307393T3 DK 09767695 T DK09767695 T DK 09767695T DK 2307393 T3 DK2307393 T3 DK 2307393T3
- Authority
- DK
- Denmark
- Prior art keywords
- abt
- preparing
- apoptosis promoter
- apoptosis
- promoter
- Prior art date
Links
- 230000006907 apoptotic process Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 title 1
- 229950004847 navitoclax Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7439008P | 2008-06-20 | 2008-06-20 | |
| US12/486,361 US8168784B2 (en) | 2008-06-20 | 2009-06-17 | Processes to make apoptosis promoters |
| PCT/US2009/047723 WO2009155386A1 (en) | 2008-06-20 | 2009-06-18 | A process for the preparation of the apoptosis promoter abt-263 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2307393T3 true DK2307393T3 (da) | 2013-07-15 |
Family
ID=41431910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09767695.1T DK2307393T3 (da) | 2008-06-20 | 2009-06-18 | Fremgangsmåde til fremstilling af apoptosepromotoren ABT-263 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8168784B2 (da) |
| EP (1) | EP2307393B1 (da) |
| JP (1) | JP5604424B2 (da) |
| KR (1) | KR20110019440A (da) |
| CN (1) | CN102131792B (da) |
| AU (1) | AU2009260044B2 (da) |
| BR (1) | BRPI0914311A2 (da) |
| CA (1) | CA2727932A1 (da) |
| CY (1) | CY1114242T1 (da) |
| DK (1) | DK2307393T3 (da) |
| ES (1) | ES2409263T3 (da) |
| HR (1) | HRP20130635T1 (da) |
| IL (1) | IL209807A (da) |
| MX (1) | MX2010014224A (da) |
| NZ (1) | NZ589732A (da) |
| PL (1) | PL2307393T3 (da) |
| PT (1) | PT2307393E (da) |
| RU (1) | RU2514935C2 (da) |
| SI (1) | SI2307393T1 (da) |
| TW (1) | TWI454471B (da) |
| WO (1) | WO2009155386A1 (da) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UY32668A (es) * | 2009-05-26 | 2010-12-31 | Abbott Lab | Agentes inductores de la apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| TWI471321B (zh) * | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| MX2012003408A (es) * | 2009-09-20 | 2012-08-03 | Abbott Lab | Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2. |
| CA2780177A1 (en) * | 2009-12-22 | 2011-06-30 | Abbott Laboratories | Abt-263 capsule |
| UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| CN101798292A (zh) * | 2010-03-29 | 2010-08-11 | 无锡好芳德药业有限公司 | ABT-263衍生的新型Bcl-2蛋白抑制剂的制备 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| CN103261186A (zh) | 2010-12-13 | 2013-08-21 | 诺瓦提斯公司 | 二聚化iap抑制剂 |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| CN102584744B (zh) * | 2011-01-06 | 2015-07-01 | 上海药明康德新药开发有限公司 | 4-(4-((2-(4-氯苯基)-5,5-二甲基环己基-1-烯)甲基)哌嗪-1-基)苯甲酸的合成方法 |
| JP5898419B2 (ja) * | 2011-06-07 | 2016-04-06 | 公益財団法人相模中央化学研究所 | （トリフルオロメチルスルホニル）ベンゼン誘導体の製造方法 |
| BR112014016870A2 (pt) | 2012-01-09 | 2017-06-27 | Huesken Dieter | composições orgânicas para tratar doenças relacionadas com beta-catenina |
| DK2958907T3 (da) | 2013-02-19 | 2018-06-06 | Novartis Ag | Benzothiophenderivater og sammensætninger dermed som selektive østrogenreceptornedbrydere |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| MX366978B (es) | 2013-03-15 | 2019-08-01 | Novartis Ag | Conjugados de anticuerpo - farmaco. |
| FR3008093B1 (fr) * | 2013-07-04 | 2015-12-11 | Rhodia Operations | Procede de fluoration de composes halogenures de sulfonyle |
| WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
| CN105899491B (zh) | 2014-01-17 | 2019-04-02 | 诺华股份有限公司 | 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| EP3139942B1 (en) | 2014-05-05 | 2019-12-18 | Bioventures, Llc | COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS |
| AU2015292710A1 (en) | 2014-07-22 | 2017-02-16 | Bioventures, Llc. | Compositions and methods for selectively depleting senescent cells |
| WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| KR20170040249A (ko) | 2014-08-12 | 2017-04-12 | 노파르티스 아게 | 항-cdh6 항체 약물 접합체 |
| PE20170912A1 (es) | 2014-11-14 | 2017-07-12 | Novartis Ag | Conjugados de anticuerpo-farmaco |
| ES2722048T3 (es) | 2014-12-23 | 2019-08-07 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos |
| RU2017134379A (ru) | 2015-03-25 | 2019-04-03 | Новартис Аг | Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4 |
| EP3310813A1 (en) | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
| CN112625028B (zh) | 2015-06-19 | 2024-10-29 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
| EP3310771B1 (en) | 2015-06-19 | 2020-07-22 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| EP3341023A1 (en) | 2015-08-28 | 2018-07-04 | Novartis AG | Combination therapy using pi3k inhbitor and mdm2 inhibitor |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| US11027021B2 (en) | 2016-03-15 | 2021-06-08 | Seagen Inc. | Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors |
| WO2017172826A1 (en) | 2016-03-28 | 2017-10-05 | Presage Biosciences, Inc. | Pharmaceutical combinations for the treatment of cancer |
| KR102447884B1 (ko) | 2016-04-21 | 2022-09-27 | 바이오벤처스, 엘엘씨 | 항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도 |
| US10577362B2 (en) | 2016-05-04 | 2020-03-03 | Genoscience Pharma | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases |
| WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| EP3472166A1 (en) | 2016-06-20 | 2019-04-24 | Novartis AG | Imidazopyrimidine compounds useful for the treatment of cancer |
| US11091489B2 (en) | 2016-06-20 | 2021-08-17 | Novartis Ag | Crystalline forms of a triazolopyrimidine compound |
| EP3472161B1 (en) | 2016-06-20 | 2020-03-25 | Novartis AG | Triazolopyridine compounds and uses thereof |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| US11179413B2 (en) | 2017-03-06 | 2021-11-23 | Novartis Ag | Methods of treatment of cancer with reduced UBB expression |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| US20200362058A1 (en) | 2017-05-24 | 2020-11-19 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
| WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
| IL322309A (en) | 2017-05-24 | 2025-09-01 | Novartis Ag | IL2 antibody grafted proteins and methods of use in cancer treatment |
| TWI851542B (zh) | 2017-09-11 | 2024-08-11 | 美商克魯松藥物公司 | Ｓｈｐ２之八氫環戊烷并[c]吡咯別構抑制劑 |
| JP7385284B2 (ja) | 2018-01-22 | 2023-11-22 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニー | 癌処置のためのｂｃｌ－２タンパク質分解剤 |
| SI3788042T1 (sl) | 2018-04-29 | 2025-06-30 | Beigene Switzerland Gmbh | Zaviralci BCL-2 |
| WO2019221755A1 (en) | 2018-05-18 | 2019-11-21 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CA3103385A1 (en) | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
| AU2019344897B2 (en) | 2018-09-18 | 2024-01-18 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors |
| CN113382986A (zh) | 2018-09-25 | 2021-09-10 | 黑钻治疗公司 | 酪氨酸激酶抑制剂组合物、其制备方法和使用方法 |
| JP2022502496A (ja) | 2018-09-25 | 2022-01-11 | ブラック ダイアモンド セラピューティクス，インコーポレイティド | チロシンキナーゼ阻害剤組成物、作製方法、および使用方法 |
| CA3113379A1 (en) | 2018-09-29 | 2020-04-02 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
| WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| KR20210107731A (ko) | 2018-12-21 | 2021-09-01 | 노파르티스 아게 | Pmel17에 대한 항체 및 이의 접합체 |
| CN109851535A (zh) * | 2019-01-30 | 2019-06-07 | 天津现代职业技术学院 | 一种制备4-氟-3-(三氟甲磺酰基)苯磺酰胺的方法 |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| ES2982474T3 (es) | 2019-02-15 | 2024-10-16 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos |
| TW202045174A (zh) | 2019-02-28 | 2020-12-16 | 日商富士軟片股份有限公司 | 組合醫藥 |
| US20220257698A1 (en) | 2019-08-02 | 2022-08-18 | Lanthiopep B.V. | Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer |
| CN114787150A (zh) | 2019-08-15 | 2022-07-22 | 黑钻治疗公司 | 炔基喹唑啉化合物 |
| WO2021057853A1 (en) | 2019-09-26 | 2021-04-01 | Novartis Ag | Aza-quinoline compounds and uses thereof |
| JP2022553820A (ja) | 2019-11-05 | 2022-12-26 | アッヴィ・インコーポレイテッド | 骨髄線維症及びｍｐｎ関連障害をナビトクラクスで処置する際に使用するための投与レジメン |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| WO2021195206A1 (en) | 2020-03-24 | 2021-09-30 | Black Diamond Therapeutics, Inc. | Polymorphic forms and related uses |
| WO2021208963A1 (en) | 2020-04-15 | 2021-10-21 | Beigene, Ltd. | Bcl-2 inhibitor |
| US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| MX2022015852A (es) | 2020-06-23 | 2023-01-24 | Novartis Ag | Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| EP4175644A1 (en) | 2020-07-06 | 2023-05-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AR123185A1 (es) | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
| EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022140472A1 (en) | 2020-12-22 | 2022-06-30 | Nikang Therapeutics, Inc. | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway |
| WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| WO2022170052A1 (en) | 2021-02-05 | 2022-08-11 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| EP4323350A1 (en) | 2021-04-14 | 2024-02-21 | Monte Rosa Therapeutics AG | Isoindolinone compounds |
| EP4323349A1 (en) | 2021-04-14 | 2024-02-21 | Monte Rosa Therapeutics AG | Isoindolinone amide compounds useful to treat diseases associated with gspt1 |
| CA3216880A1 (en) | 2021-04-16 | 2022-10-20 | Novartis Ag | Antibody drug conjugates and methods for making thereof |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2023284730A1 (en) | 2021-07-14 | 2023-01-19 | Nikang Therapeutics, Inc. | Alkylidene derivatives as kras inhibitors |
| US20250099440A1 (en) | 2021-08-02 | 2025-03-27 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical combination and use thereof |
| US20250154141A1 (en) | 2021-12-09 | 2025-05-15 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders for treatment of cancers |
| US12331026B2 (en) | 2022-03-28 | 2025-06-17 | Nikang Therapeutics, Inc. | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2023240024A1 (en) | 2022-06-08 | 2023-12-14 | Nikang Therapeutics, Inc. | Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors |
| EP4562010A1 (en) | 2022-07-26 | 2025-06-04 | Novartis AG | Crystalline forms of an akr1c3 dependent kars inhibitor |
| AU2023375457A1 (en) | 2022-11-11 | 2025-05-01 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
| WO2025072462A1 (en) | 2023-09-27 | 2025-04-03 | Nikang Therapeutics, Inc. | Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
| TW202527955A (zh) | 2023-11-27 | 2025-07-16 | 美商尼坎醫療公司 | 用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶２和週期蛋白依賴性激酶４的含有２，５－取代的嘧啶衍生物的雙功能化合物 |
| WO2025117981A1 (en) | 2023-12-02 | 2025-06-05 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
| WO2025212828A1 (en) | 2024-04-03 | 2025-10-09 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway |
| WO2025240536A1 (en) | 2024-05-15 | 2025-11-20 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4469794B2 (ja) * | 2003-02-25 | 2010-05-26 | 神戸天然物化学株式会社 | ビタミンｄ誘導体を合成するための新規な中間体 |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| DK1888550T3 (da) | 2005-05-12 | 2014-09-29 | Abbvie Bahamas Ltd | Apoptosepromotorer |
| JP5366817B2 (ja) | 2006-11-15 | 2013-12-11 | ジェネンテック， インコーポレイテッド | アリールスルホンアミド化合物 |
-
2009
- 2009-06-17 US US12/486,361 patent/US8168784B2/en active Active
- 2009-06-18 WO PCT/US2009/047723 patent/WO2009155386A1/en not_active Ceased
- 2009-06-18 DK DK09767695.1T patent/DK2307393T3/da active
- 2009-06-18 NZ NZ589732A patent/NZ589732A/xx not_active IP Right Cessation
- 2009-06-18 CN CN200980132472.XA patent/CN102131792B/zh not_active Expired - Fee Related
- 2009-06-18 EP EP09767695.1A patent/EP2307393B1/en not_active Not-in-force
- 2009-06-18 CA CA2727932A patent/CA2727932A1/en not_active Abandoned
- 2009-06-18 AU AU2009260044A patent/AU2009260044B2/en not_active Ceased
- 2009-06-18 ES ES09767695T patent/ES2409263T3/es active Active
- 2009-06-18 JP JP2011514792A patent/JP5604424B2/ja not_active Expired - Fee Related
- 2009-06-18 SI SI200930640T patent/SI2307393T1/sl unknown
- 2009-06-18 MX MX2010014224A patent/MX2010014224A/es active IP Right Grant
- 2009-06-18 PL PL09767695T patent/PL2307393T3/pl unknown
- 2009-06-18 HR HRP20130635AT patent/HRP20130635T1/hr unknown
- 2009-06-18 BR BRPI0914311A patent/BRPI0914311A2/pt not_active IP Right Cessation
- 2009-06-18 RU RU2011101951/04A patent/RU2514935C2/ru not_active IP Right Cessation
- 2009-06-18 PT PT97676951T patent/PT2307393E/pt unknown
- 2009-06-18 KR KR1020117001475A patent/KR20110019440A/ko not_active Abandoned
- 2009-06-19 TW TW098120701A patent/TWI454471B/zh not_active IP Right Cessation
-
2010
- 2010-12-06 IL IL209807A patent/IL209807A/en not_active IP Right Cessation
-
2013
- 2013-06-18 CY CY20131100489T patent/CY1114242T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2307393B1 (en) | 2013-04-10 |
| US20090318689A1 (en) | 2009-12-24 |
| WO2009155386A1 (en) | 2009-12-23 |
| RU2011101951A (ru) | 2012-07-27 |
| KR20110019440A (ko) | 2011-02-25 |
| TWI454471B (zh) | 2014-10-01 |
| JP5604424B2 (ja) | 2014-10-08 |
| MX2010014224A (es) | 2011-01-21 |
| SI2307393T1 (sl) | 2013-08-30 |
| PL2307393T3 (pl) | 2013-09-30 |
| AU2009260044B2 (en) | 2013-08-29 |
| AU2009260044A1 (en) | 2009-12-23 |
| IL209807A0 (en) | 2011-02-28 |
| JP2011525182A (ja) | 2011-09-15 |
| HRP20130635T1 (en) | 2013-08-31 |
| US8168784B2 (en) | 2012-05-01 |
| ES2409263T3 (es) | 2013-06-26 |
| TW201002700A (en) | 2010-01-16 |
| CA2727932A1 (en) | 2009-12-23 |
| CN102131792A (zh) | 2011-07-20 |
| PT2307393E (pt) | 2013-06-27 |
| CY1114242T1 (el) | 2016-08-31 |
| HK1154568A1 (en) | 2012-04-27 |
| RU2514935C2 (ru) | 2014-05-10 |
| IL209807A (en) | 2014-08-31 |
| CN102131792B (zh) | 2014-05-07 |
| EP2307393A1 (en) | 2011-04-13 |
| NZ589732A (en) | 2012-08-31 |
| BRPI0914311A2 (pt) | 2019-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2307393T3 (da) | Fremgangsmåde til fremstilling af apoptosepromotoren ABT-263 | |
| DK2496562T3 (da) | Fremgangsmåde til fremstilling af calcobutrol | |
| DK2207779T3 (da) | Fremgangsmåde til syntese af morpholinooligomerer | |
| DK2114886T3 (da) | Fremgangsmåde til fremstilling af visse substituerede sulfiliminer | |
| NO20091125L (no) | Stigerorsklemme | |
| DK2155838T3 (da) | Fremgangsmåde til fremstilling af forgrenede carbonhydrider | |
| DK2509427T3 (da) | Fremgangsmåder til fremstilling af GH8-xylanasevarianter | |
| DK2285779T3 (da) | Fremgangsmåde til fremstilling af arylcarboxamider | |
| SMT201600045B (it) | Composti tetraciclinici c7-fluoro sostituiti | |
| DK2311970T3 (da) | Fremgangsmåde til fremstillingen af bioprodukter | |
| DK2358661T3 (da) | Fremgangsmåde til fremstilling af trans-4-amino-cyclohexyl-eddikesyreethylester-hcl | |
| DK2391225T3 (da) | Fremgangsmåde til fremstilling af lactoferrin | |
| UY33156A (es) | Nuevos compuestos tienopirrol | |
| DK2382232T3 (da) | Fremgangsmåde til fremstilling af bivalirudin | |
| DK2213654T3 (da) | Fremgangsmåde til fremstilling af 2-amino-5-brombenzamid derivater | |
| DK2310613T3 (da) | Forbedret brudled til stigrør | |
| DK2253608T4 (da) | Fremgangsmåde til fremstilling af forgrenede mættede kulbrinter | |
| DK2582673T3 (da) | Fremgangsmåde til fremstilling af 2,2-difluorethylamin-derivater ved hjælp af alkylering med 2,2-difluor-1-halogenethaner | |
| DK2421819T3 (da) | Fremgangsmåde til iodering af aromatiske forbindelser | |
| EP2169142A4 (en) | METHOD FOR MANUFACTURING FLOOR | |
| DK2403827T3 (da) | Fremgangsmåde til fremstilling af ajoen | |
| DK2516359T3 (da) | Fremgangsmåde til fremstilling af ethylbenzen | |
| DK2426124T3 (da) | Fremgangsmåde til fremstilling af pyripyropene derivater | |
| DK2251168T3 (da) | Fremgangsmåde til fremstilling af træplader | |
| DK2310012T3 (da) | Fremgangsmåde til fremstilling af substituerede pyrimidinderivater |